You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1586 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
zolbetuximab (Unfunded),
CISplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
zolbetuximab,
CARBOplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab (Unfunded),
CISplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zolbetuximab (Unfunded),
CARBOplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Drug
Other Name(s): Asparlas®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2025
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Updated
Mar 2025
Document
New
Apr 2025
Document
New
Apr 2025

Pages